Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod vs. Fluorouracil vs. Observation for Anal HSIL in HIV-Positive Patients
NCT02059499Phase 3Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Dec 2015
- Primary completion
- Dec 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 3 trial of imiquimod, fluorouracil in Squamous Intraepithelial Lesion (SIL), sponsored by AIDS Malignancy Consortium. Started Dec 2015; status: completed.
02
Drugs
imiquimodfluorouracil
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT02059499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059499.